Examples of representative epidrugs and epidrug candidates are azacytidine (DNMT1 inhibitor), 5-aza-2'deoxycytidine (DNMTs and HDACs inhibitor), procaine (DNMTs inhibitor), hydralazine (DNMTs inhibitor), vorinostat (HDACs inhibitor), romidepsin (HDACs inhibitor), panobinostat (HDACs inhibitor), and belinostat (HDACs inhibitor). Nanaomycin A is a promising probe molecule (DNMT3b inhibitor). The chemical structures are shown in Figure . One of the most promising areas of this search is the field of nutriepigenomics, focused on the study of the interaction between food nutrients and genome through epigenetic mechanisms, modulating the overexpression or silencing of specific genes and metabolic responses. The interaction between nutrition, epigenetic targets, and the development of certain diseases such as type I and type II diabetes, inflammatory diseases, liver fibrosis, and cancer have been discussed in the last few years, leading to new alternatives to mitigate the damage or prevent such conditions. Using chemoinformatics to analyze natural products and food chemical data sets is increasingly widespread. The term foodinformatics, coined in 2014, captures chemical information's application to food science. Several studies focused on the contents and diversity of food chemicals have been published, yielding useful information to organize and mine chemical information associated with food chemicals, which, ultimately, is at the core of informatics applications in chemistry. Similarly, chemoinformatics has a growing interest in natural product research, giving rise to the sub-field of natural products informatics. Notable examples of the applications of chemoinformatics to food chemistry and natural product research are the development of large compound databases such as FooDB 26 and the Collection of Open Natural Products (COCONUT). Despite the increasing evidence of the effect of food and natural products chemicals on epigenetic targets, there needs to be a comprehensive survey of the effect of food molecules on different epigenetic targets rather than focusing on a specific disease or a specific epigenetic target family.